CareDx said validation data from the ACROBAT observational study support commercialization plans for AlloHeme, its cell‑free DNA assay for allogeneic hematopoietic cell transplant surveillance. The test demonstrated 85% sensitivity, 92% specificity and a median 41‑day lead time in detecting clinical relapse compared with standard-of-care monitoring in the multicenter study. CareDx will publish the ACROBAT results and said publication is a prerequisite for commercial rollout next year. Clinicians noted the assay’s negative predictive value could significantly reduce invasive bone‑marrow biopsies and enable earlier therapeutic interventions, positioning AlloHeme as a potential standard surveillance tool in post‑transplant care.